Dunlop'S 20% W/V Pmd Solution For Injection
Revised: July 2010
ATCVet code amended
SUMMARY OF PRODUCT CHARACTERISTICS
1. Name of the veterinary medicinal product
Dunlops 20% w/v PMD Solution for Injection
2. Qualitative and quantitative composition
Active Substance:
Contains Calcium Gluconate 16.6% w/v
Magnesium Hypophosphite Hexahydrate 5% w/v
Glucose Monohydrate 22.0% w/v
Each 400 ml contains:
5.92 g calcium (provided by calcium gluconate and calcium borogluconate)
1.84 g magnesium (provided by magnesium hypophosphite hexahydrate)
80 g glucose provided by glucose monohydrate.
Also contains 3.40% w/v boric aid.
Excipients:
Chlorocresol 0.1% w/v
For a full list of excipients, see section 6.1
3. Pharmaceutical form
Solution for injection
A clear, pale yellow aqueous solution
4. Clinical Particulars
4.1 Target species
Sheep
4.2 Indications for use, specifying the target species
For the treatment of hypocalcaemia complicated by deficiency of magnesium with accompanying hypoglycaemia. In the treatment of pregnancy toxaemia and other metabolic imbalances in periparturient sheep
4.3 Contraindications
Not to be administered by intravenous or intramuscular routes
4.4 Special Warnings for each target species
No special warning.
4.5 Special precautions for use
Special precautions for use in animals
The solution should be warmed to body temperature before administration.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Care should be taken to avoid accidental self-injection.
If accidental self-injection occurs, seek medical advice. Wash hands after use.
4.6 Adverse reactions (frequency and seriousness)
None
4.7 Use during pregnancy, lactation or lay
Can be safely administered to pregnant and lactating animals
4.8 Interaction with other medicinal products and other forms of interaction
None known
4.9 Amounts to be administered and administration route
The solution should be warmed to body temperature before administration by subcutaneous injection only. Observe aseptic precautions. Sites of administration should be massaged gently.
Sheep: 50 - 80 ml
Overdose (symptoms, emergency procedures, antidotes), if necessary
Not applicable.
Withdrawal period
Meat – Zero days
Milk – Zero hours
5. pharmacological properties
Pharmacotherapeutic group: Mineral supplements, Calcium, Calcium, combinations with other drugs
ATC Vet Code: QA12AX
5.1 Pharmacodynamic properties
Milk fever, characterised by hypocalcaemia is caused by an acute drop in the level of calcium in the blood. At parturition hypophosphataemia and hypomagnesaemia can also occur. When administered by subcutaneous injection the product replenishes plasma concentrations of calcium, phosphate and magnesium ions. Dextrose is included as an energy source to coincide with the high turnover of energy during lambing.
6. Pharmaceutical particulars
6.1 List of excipients
Chlorocresol
Sodium Bicarbonate (for pH adjustment)
Water for Injection
6.2 Incompatibilities
None known
Shelf life
Shelf life of the veterinary medicinal product as packaged for sale:
Amber Glass Bottles 2 years.
Polypropylene Vials 2 years.
Shelf life after first opening the immediate packaging: 28 days
Special precautions for storage
(1) Following withdrawal of the first dose use the contents within 28 days. Discard unused material.
(2) Do not store above 25°C.
(3) Protect from light.
Nature and composition of immediate packaging
400 ml amber Type III glass bottles, with natural rubber wads and aluminium screw caps or 400 ml polypropylene vials with bromobutyl bungs and aluminium overseals
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Norbrook Laboratories Limited
Station Works
Newry
Co. Down, BT35 6JP
8. MARKETING AUTHORISATION NUMBER(S)
Vm02000/4206
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 23rdMay 2000
10. DATE OF REVISION OF THE TEXT
July 2010
4